Aclaris Therapeutics (ACRS) Tops Q3 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $1.36 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Paramount Skydance clears global regulators for WBD deal, faces state AG suit
• Active options: AVGO MSTR PLTR SNDK SMCI NBIS MSFT META GOOGL NU NFLX ONDS